Related Experiment Videos
Primary central nervous system lymphoma: a review
1Legacy Brain and Spinal Cord Tumor Service, Legacy Cancer Services, Legacy Hospital System, 1040 NW 22nd Avenue, Portland, OR 97210, USA. lesliemcallister@hotmail.com
Current Neurology and Neuroscience Reports
|April 9, 2002
Summary
Primary central nervous system lymphoma (PCNSL) is an aggressive brain cancer. High-dose methotrexate-based chemotherapy improves survival for PCNSL patients, offering a promising treatment strategy.
Area of Science:
- Oncology
- Neurology
- Hematology
Background:
- Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma.
- Increasing incidence observed in immunocompetent individuals.
- Nonspecific neurological or visual symptoms and characteristic imaging findings are typical presentations.
Purpose of the Study:
- To review the current understanding and treatment strategies for PCNSL.
- To highlight the efficacy of methotrexate-based chemotherapy.
- To discuss the challenges and future directions in PCNSL management.
Main Methods:
- Literature review of PCNSL diagnosis and treatment.
- Analysis of treatment outcomes, focusing on chemotherapy regimens.
- Discussion of diagnostic procedures including stereotactic biopsy and CSF cytology.
Main Results:
- High-dose methotrexate-based chemotherapy significantly improves survival compared to radiotherapy alone.
- Corticosteroids can interfere with diagnosis and should be used cautiously.
- Combined chemo-radiotherapy is associated with late neurologic toxicities, particularly in older patients.
Conclusions:
- Methotrexate-containing regimens are crucial for improving PCNSL survival rates.
- Further research into lymphoma biology is needed for enhanced treatment strategies.
- Future trials should prioritize survival improvement while minimizing long-term neurological side effects.